EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Viva Biotech Holdings's Enterprise Value is €293.6 Mil.
Viva Biotech Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €13.3 Mil. Therefore, Viva Biotech Holdings's EV-to-FCF for today is 22.12.
The historical rank and industry rank for Viva Biotech Holdings's EV-to-FCF or its related term are showing as below:
FRA:VB0'
s EV-to-FCF Range Over the Past 10 Years
Min: -828.4 Med: -8.28 Max: 51.72
Current: 21.7
During the past 10 years, the highest EV-to-FCF of Viva Biotech Holdings was 51.72. The lowest was -828.40. And the median was -8.28.
FRA:VB0's EV-to-FCF is ranked worse than 60.12% of 336
companies
in the Biotechnology industry
Industry Median: 14.885
vs FRA:VB0: 21.70
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Viva Biotech Holdings's PE Ratio (TTM) for today is calculated as:
Viva Biotech Holdings's share price for today is €0.119.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Viva Biotech Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's EV-to-FCF falls into.
Viva Biotech Holdings's current Enterprise Value is €293.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €13.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a EV-to-FCF of 22.12 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Viva Biotech Holdings and its competitors. According to the industry distribution chart, Viva Biotech Holdings ranks #202 out of 336 companies in the Biotechnology industry, placing it in the top 60.1%.
Is Viva Biotech Holdings' EV-to-FCF too high?
Viva Biotech Holdings' current EV-to-FCF is 22.12. The Biotechnology industry median EV-to-FCF is 14.89. Viva Biotech Holdings' value of 22.12 is 48.6% above this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #202 out of 336 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #202 out of 336 companies for EV-to-FCF. This places Viva Biotech Holdings in the lower half of its industry. The industry median EV-to-FCF is 14.89. Viva Biotech Holdings' value of 22.12 is 48.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.89, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current EV-to-FCF of 22.12 is 48.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current EV-to-FCF is 22.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 48.8% above its estimated fair value. The current EV-to-FCF is 22.12 and 48.6% above the Biotechnology industry median of 14.89. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current EV-to-FCF is 22.12 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.12 is trading 48.8% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
EV-to-FCF: 22.12
GF Value™: €0.08 vs. price of €0.12 (48.8% above fair value)
Industry Position: 48.6% above the Biotechnology median (#202 of 336)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
